Toxicoproteomics - A new preclinical tool

Drug Discovery Today

Volumn 7, Issue 7, 2002, Pages 411-418

  Bandara, Lasantha R ^a   Kennedy, Sandy ^a  

^a Oxford GlycoSciences   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CALBINDIN; CYCLOSPORIN A; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; GENTAMICIN; MEPYRAMINE; METHAPYRILENE; NAFENOPIN; PARACETAMOL; PIRINIXIC ACID; RAZOXANE; SDZPGU 693; UNCLASSIFIED DRUG; PROTEOME;

ANALYTIC METHOD; CARCINOGENICITY; CARDIOTOXICITY; DISEASE MARKER; DRUG RESEARCH; DRUG TARGETING; GENETIC TRAIT; GENOME; GENOMICS; HUMAN; LIVER TOXICITY; NONHUMAN; PREDICTION; PROTEIN FUNCTION; PROTEOMICS; PUBLISHING; REVIEW; SCREENING; TOXICOLOGY; TOXICOPROTEOMICS; ANIMAL; COMPUTER SIMULATION; DRUG SCREENING; GENETICS; MICROCOMPUTER; PHARMACOLOGY;

ANIMAL; COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; HUMAN; MICROCOMPUTERS; PHARMACOLOGY; PROTEOME; PROTEOMICS; TOXICOLOGY; ANIMALS; HUMANS;

EID: 0036525708     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02211-0     Document Type: Review

References (54)

1. Pharmacogenetics, genomics, proteomics: The new frontiers in drug development
2. Proteome and proteomics: New technologies, new concepts and new words
3. Proteomics: Quantitative and physical mapping of cellular proteins
4. General Introduction and Study design and regularity requirements
5. Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties
6. Data mining of spectroscopic data for biomarker discovery
7. Mass spectrometry for protein and peptide characterisation
8. Proteomic profiling from human samples: The body fluid alternative
9. The principles and practice of toxicogenomics: Applications and opportunities
10. Advances in molecular toxicology - Towards understanding idiosyncratic drug toxicity
11. Simultaneous measurement of hundreds of liver proteins: Application in assessment of liver function
12. The hepatocarcinogen methapyrilene but not the analogue pyrilamine induces sustained hepatocellular replication and protein alterations in F344 rats in a 13 week feed study
13. Changes in the liver protein pattern of female Wistar rats treated with the hypoglycemic agent SDZPGU693
14. The effects of peroxisome proliferators on protein abundances in mouse liver
15. A proteome analysis of livers from obese (ob/ob) mice treated with the peroxisome proliferator WY 14,643
16. Two-dimensional database of mouse liver proteins: Changes in hepatic protein levels following treatment with acetaminophen or its nontoxic regioisomer 3-acetamidophenol
17. Cyclosporine A decreases the protein level of the calcium binding protein calbindin-D 28 kDa in rat kidney
18. New insights into cyclosporine A nephrotoxicity by proteome analysis
19. An integrated approach to studying glomerular nephrotoxicity
20. Regional protein alterations in rat kidneys induced by lead exposure
21. Alterations in rabbit kidney protein expression following lead exposure as analysed by two-dimensional gel electrophoresis
22. Molecular and cellular mechanisms of cardiotoxicity
23. Anthracycline-induced cardiotoxicity: Clinical course, risk factors, pathogenesis, detection and prevention - Review of the literature
24. Retrospective analysis of the safety of herceptin® immunotherapy in metastatic breast cancer
25. Cardiotoxicity of chemotherapeutic agents: Incidence, treatment and prevention
26. Mechanism of the cardiotoxic actions of tefenadine
27. 2) cyclophosphomide
28. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity
29. Cardiovascular proteomics: Evolution and potential
30. Applications of proteomics to the study of cardiovascular biology
31. Protein changes observed in pacing-induced heart failure using two-dimensional electrophoresis
32. Identification and characterisation of heat shock protein 27 species in human myocardial two-dimensional electrophoresis patterns
33. Identification of gel separated tumour marker proteins by mass spectrometry
34. Proteomics in human disease: Cancer, heart and infectious diseases
35. Proteomic-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer
36. Proteomic analysis of differential protein expression in primary hepatocytes induced by EGF, tumour necrosis factor or the peroxisome proliferator nafenopin
37. Two-dimensional gel electrophoresis: A powerful method to elucidate cellular responses to toxic compounds
38. A protein expression database for the molecular pharmacology of cancer
39. An information-intensive approach to the molecular pharmacology of cancer
40. New active substances authorized in the United Kingdom between 1972 and 1994
41. Incidence of adverse drug reactions in hospitalised patients
42. The environment and disease: Association or causation?
43. Protein biochips for differential profiling
44. Protein and antibody arrays and their medical applications
45. Arrays for protein expression profiling: Towards a viable alternative to two-dimensional gel electrophoresis
46. ProteinChip surface enhanced laser desorption/ionisation (SELDI) mass spectrometry: A novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures
47. Mass spectrometry meets chip technology: A new proteomic tool in cancer research?
48. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags
49. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network
50. Application of genomics to the definition of the molecular basis for toxicity
51. Gene expression microarray data analysis for toxicology profiling
52. Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles
53. Pharmacogenetics and adverse drug reactions
54. Genetic susceptibility to adverse drug reactions